\n \n \n “. concat(self. i18n. t(‘search. voice. recognition_retry’), “\n
PRESS RELEASE
Paris, 25 August 2022
Provisional annual effects at the end of June 2022
The nordics’ smart functionality led to an improvement in the effects of Ramsay Health Group, despite persistent demanding situations of high inflation, nursing and clinical shortages, and the ongoing pandemic, in which Ramsay Health continued to play a role. prominence in Europe.
In line with its Yes We Care 2025 strategic plan, Ramsay Santé continued its investments at a point comparable to previous years to position itself with patients as a global and embedded healthcare player in continental Europe.
With more than 10,000 COVID patients treated in France, totaling 4,500 in intensive care, Ramsay Health has remained committed to fighting COVID for the past 12 months. In Sweden, we continue to take on the duty to care about COVID patients and restricting the effects of the pandemic on Americans and society. For example, approximately 600,000 doses of the COVID vaccine were administered to patients, in our Swedish services, especially to the citizens of our nursing homes. In addition, we continue to manage nearly 20% of all COVID-related hospital care in the Stockholm area.
Growth was strong in the 3 Nordic countries, specifically in medical, surgical and obstetric hospitalizations (MSO), 14% more than the previous year, Germany. Consultations in the number one care centers in Sweden, adding teleconsultations, increasing up to 16%. In France, complete hospitalizations in MSO were minimized by 4. 1%, while day hospitalizations increased by 3%. The same trend affects our Rehabilitation and Follow-up Care (FCR) business with a 1. 1% reduction in inpatients and a 27. 6% cumulative in outpatients.
Total investments of the era amounted to €217 million compared to €220 million last year. More than 40% of investments correspond to expansion and virtual investments. These investments are mandatory for our operational and medical excellence. The number one care center number highest through 28% from 130 to 167 in 2022. We opened our first five number one care centers in France and invested in 2 new surgical robots. We also established operational and equity partnerships with startups Resilience and NewCard. In January 2022, we introduced Ramsay Services, a virtual platform.
Reported annual profit of 4,301 million euros, up 6. 9%. Restated by adjustments in scope and at consistent exchange rates, profit for the year ended June 30, 2022 increases with a closely forged biological benefit expansion of 6. 0%.
Reported EBITDA increased by 2. 3% to €658. 4 million (previous year, €643. 8 million) with a margin of 15. 3% (16. 0% last year). The evolution of EBITDA definitely impacted through the activity in the Nordic countries, which compensated for the accumulation in inflation and the set of workers’ costs. The profit guarantee scheme established through the French State generated €99 million of profits in the year ended June 30, 2022, compared to a profit source of €103 million in the year ended June 30, 2021.
The percentage of the Group’s net revenue source amounts to €118. 4 million, benefiting from the accumulation of activity and staggered results, which represent 2. 8% of revenues.
Net monetary debt as of June 30, 2022 amounts to €3. 71 billion, totalling €2. 118 billion in IFRS 16 liabilities.
Pascal Roché, CEO of Ramsay Santé says:
“In 2022, for the first time, Ramsay Santé exceeded the threshold of 10 million patients treated in Europe in its activities, inside and outside its establishments, as well as digitally. During the year, the Group mobilized more than ever to care for Covid patients and strengthened its capacity to care for all patients with all pathologies. In France, our commitment is reflected in the fact that 10% of admitted patients benefit from Universal Medical Coverage (CMU). The Group has also initiated a cutting-edge technique in the field of human resources in France with the signing of an ambitious agreement on the quality of life at work. Monetary effects remain solid, with an expansion of 6. 9% and a slightly reduced EBITDA margin (15. 3% under IFRS16 in 2022 vs. 16. 0% in 2021). These effects are due to sustained biological expansion as well as acquisitions in Sweden, Norway and Denmark. This demonstrates the relevance of our strategy to consolidate our position as an incorporated European healthcare operator and orchestrate coordinated healthcare pathways, allowing us to guarantee quality and accessibility for all.
These provisional accounts were presented to the Board of Directors at its meeting on 25 August 2022. The audit procedure is in full swing. The last monetary statements for the year ended June 30, 2022 will be made available to the public at the time of publication of the Company’s Universal Registration Document at the end of October 2022.
Summary of Results
in euros
From July 1, 2021 to June 30, 2022
Variation
From July 1, 2020 to June 30, 2021
Rotation
4 301. 0
6,9%
4 022,6
EBITDA (IFRS 16)
658. 4
2,3%
643. 8
Underlying income
281. 1
3,3%
272,0
% Turnover
6,5%
-0. 3 points
6,8%
Operating profit
291. 2
16,2%
250. 6
Net source of revenue Group share
118. 4
65,0
Consistent earnings with consistent percentage (in €)
1. 07
0,59
Breakdown of profit by operating segment
in euros
From July 1, 2021 to June 30, 2022
From July 1, 2020 to June 30, 2021
Variation
Île-de-France
1 057,9
1 000,8
5,7%
Auvergne-Rhône-Alpes
579. 6
561. 7
3,2%
peaks of France
393. 4
380. 6
3,4%
Provence Alpes Côte d’Azur
169. 1
161. 4
4,8%
Burgundy Franche-Comté
133,7
107. 4
24,5%
Other regions
669. 8
655. 3
2,2%
the Nordic countries
1 297,4
1 155,4
12,3%
Reported billing
4 301. 0
4 022. 6
6. 9%
Of which: – Income with consistent scope and rates
4 215,1
3 977,4
6,0 %
– Impact of acquisitions and disposals and exchange rate fluctuations
85,9
45. 2
Note: The table above primarily indicates the contributions of the operating segments to the Group’s consolidated revenues. Highlights of the exercise:
Health due to the COVID pandemic
The financial year ended 30 June 2022 was affected by the persistent fitness crisis due to the COVID pandemic in all countries in which the Group operates.
France
In France, personal hospitals have maintained their action plans to fight the COVID epidemic and their investment point in relation to and for public hospitals, in accordance with the national fitness plan.
Ramsay Health has expanded its commitment to caring for COVID patients with more than 10,000 COVID patients treated in France, adding 4500 in intensive care. Like hospital operators, Ramsay Santé continued to receive support through measures implemented by the government. Measures of the time refer to:
The source of income guarantee
Subsidies to offset additional COVID-related costs
The source of income ensures that it covered the entire practice of Obstetric Surgery Medicine (MSO) and Follow-up care and Rehabilitation (FCR). It is only in position for the first semester (July-December 2021) for Mental Health activities, given the reform of the investment of Mental Health (HD) activities towards an allocation style in force since January 1, 2022.
The amount of the financing insurance recognized through the Group for the year ended June 30, 2022 amounts to 99 million euros (103 million euros in the last year) and is presented in the source of income in “Other sources of operating income”.
In addition to the earnings guarantee, the government has also adjusted the degrees of subsidies regularly paid to fitness services to offset additional prices similar to the COVID crisis that would not be covered otherwise. These subsidies are recognized in the source of profit in “Other sources of operating profit” for 89. 8 million euros (72. 3 million euros last year). Given the time lag between the assumption of prices through establishments and the communication through the Autonomous Communities of the corresponding subsidies, a significant component of the subsidies registered during the era corresponds to the financing of new prices that occurred during the past year, a scenario similar to that of the same was last year. Of the total funding recorded during the era, 27. 5 million euros (14. 5 million in the last year) corresponds to amounts earned for the financing of new prices committed in the last year.
outside France
The Group’s facilities in Scandinavia have played an active role in the care of COVID patients as well as in the screening and vaccination of the population, in aid of public establishments and in close collaboration with the supervisory government. However, activity has been impacted by the fitness crisis during the period, specifically for hospital care in Sweden, but also in Denmark and Norway, where the government suspended admissions at the height of the spread of the virus from December 2021 to February 2022. Despite these periods of interruption, the general point of activity and profits have been forged as activity has been boosted in periods of recovery of general activity.
In Sweden, the Sankt Göran Hospital and Geriatric Hospitals operated through the Group in Stockholm played a key role in managing the outbreak with more than a hundred beds earmarked for COVID patients. Sankt Göran, in collaboration with Stockholm Geriatric Hospitals, has treated almost 20% of all COVID patients in Stockholm dominate the pandemic. The Group has particularly contributed to the screening and vaccination effort in Sweden and screening in Norway.
While no measures have been put in place in Norway and Denmark, our services in Sweden have won subsidies to cover additional operating costs. In total, the amount of aid earned through our establishments in Sweden amounted to €32. 2 million during the period, compared to €61. 5 million in the previous period.
Consolidation perimeter
Ramsay Santé completed the acquisition of 10 entities in Scandinavia this year. These acquisitions are complementary to the existing activity and expand the scope of the Group’s facilities as well as its geographical presence. In total, these acquisitions involved a net investment of €288. 6 million.
In addition, Ramsay Healthcare completed the acquisition of GHP Specialty Care AB (“GHP”) in May 2022, for a commercial price of €238 million. In the 12 months to December 2021, GHP’s earnings were €137 million. GHP employs 765 FTEs. This acquisition contributed €29 million in profits and €1. 9 million in EBITDA to Ramsay Santé’s accounts for the year ended June 30, 2022.
Indicative offer earned through Ramsay Health Care Limited
On 20 April 2022, Ramsay Générale de Santé took note of the announcement through Ramsay Health Care Limited, its australian benchmark percentage shareholder indexed on the Sydney Stock Exchange, and confirmed that it had won a non-binding and conditional indicative offer from a consortium of investors led through KKR to obtain one hundred percent of the equity percentage of Ramsay Health Care Limited.
On 25 August 2022, Ramsay Health Care Limited issued a new announcement stating that the consortium proceeded to review the transaction and showed the terms of its indicative offering, which remains subject to certain conditions, adding the final touch of Ramsay Health Care Limited’s due diligence. and private access to data related to Ramsay General Health, and that the Board of Directors of Ramsay Générale de Santé had requested from the consortium the same previous data required in such cases to evaluate the request for access to this private data.
The full press issued through Ramsay Health Care Limited can be found on the Ramsay Health Care Limited (www. ramsayhealth. com) website.
Comments on the annual accounts
Activity and billing:
During the year ended 30 June 2022, the Ramsay Santé Group generated a consolidated profit of €4,301. 0 million compared to €4,022. 6 million for the period from 1 July 2020 to 30 June 2021, an accumulation of 6. 9%. it should be noted that the financing guarantee scheme in the Group’s accounts has no effect on the reported result as it is presented in the source of results under the heading “Other sources of operating results”.
With consistent reach and exchange rates, the Group’s profit increased by up to 6. 0% with an additional running day.
The adjustments in scope are due to the divestment of the German and two clinics in France last year, combined with acquisitions in the Nordic region in the last 12 months.
For the year ending June 30, 2022, the overall activity of Ramsay Santé’s French entities continued to be affected by the consequences of the COVID pandemic. The main effects were similar to the cancellation of certain scheduled medical-surgical activities during the peaks. of the pandemic, but also to the limitation of the number of patients in line with the room. In total, the number of patient admissions increased by 3. 2% compared to last year. This increase is basically similar to relatively small volumes in 2020-2021, as the negative effect of the COVID pandemic on patients’ willingness to access care fades into our follow-up care, rehabilitation, and intellectual fitness businesses.
The variation across the industry is broken down as follows:
0. 3% in medicine and obstetrics
23. 8% in SRH and rehabilitation
11. 4% in health
As part of its public service missions, the Group recorded a 16. 2% increase in the number of emergency room visits over the past year, with approximately 755,000 visits to our services in France.
The expansion of organic earnings in the Nordic countries for the year ended June 30, 2022 was 7. 4% compared to last year. The expansion of organic earnings was driven through investments and new contracts, more facilities similar to COVID testing and vaccinations, and continued positive earnings expansion in the underlying business. The Scandinavian business also benefited from the latest acquisitions, which generated €66 million in additional profits during the year, net of the influence of disposals (German business sold at the end of 2020).
Results:
EBITDA reached €658. 4 million in the year ended 30 June 2022, up 2. 3% in reported terms. The Group’s EBITDA as of June 30, 2022 includes €99. 1 million, similar to the profit guarantee plan described in the previous paragraph “Important occasions of the year”. , as well as the payment of COVID surcharge charges for France and Sweden. EBITDA was also definitively affected by the growth of the biological business, specifically in the Nordic region. On a comparable basis, with consistent scope and exchange rates, EBITDA increased by 1. 3% over the year.
EBITDA margin as a percentage of profit was 15. 3%, compared to 16. 0% at the same time last year on a reported basis. With a consistent scope and exchange rates, the EBITDA margin decreased from 16. 2% to 15. 4%.
The underlying source of operating income amounted to €281. 1 million between 1 July 2021 and 30 June 2022 (i. e. 6. 5% of revenue), up 3. 3% from last year.
Other sources of non-current income and expenses constitute a net source of income of €10. 2 million for the year ended 30 June 2022, consisting mainly of capital gains from the disposal of vacant properties, disposals of tangible and intangible assets and reversals of provisions similar to the disposal of Capio’s activities in Germany. From 1 July 2020 to 30 June 2021, other sources of non-current income and expenditure amounted to a net expenditure of €21. 4 million.
The net monetary debt charge amounted to €123. 5 million for the year ended 30 June 2022, to €123. 2 million last year. This includes interest on senior debt and, in accordance with IFRS 16, the Group recorded monetary interest expense of €123. 2 million. €72. 3 million assimilated to lease debt (€71. 1 million in the last year).
The Group’s net revenue source percentage for the era of 1 July 2021 to 30 June 2022 amounted to €118. 4 million, or 2. 8% of revenue, compared to €65. 0 million for the era of 1 July 2020 to 30 June 2021.
Financing:
Net monetary debt as of June 30, 2022 amounts to €3,709. 9 million to €3,230. 5 million as of June 30, 2021. Net debt includes €1,763. 6 million of non-existent debt and €35. 4 million of existing debt, offset by €132. 5 million of money and money equivalents.
The application of IFRS 16 to operating rents contributed €2,118. 3 million to monetary debt as of June 30, adding €1,922. 3 million to non-existing lease debt and €196. 0 million to existing lease debt.
During the first part of this financial year, Ramsay Santé finalized a bond factor in Euro Private Placement for a total financing amount of 100 million euros in two tranches maturing in 2027 and 2028.
The Group is assembling all commitments in a manner similar to the current financial documentation. The application of IFRS 16 does not affect how the monetary aggregates covered through those debt contracts are calculated.
About Ramsay Health
Ramsay Santé is the leader in constant consonal hospitalization and care number one in Europe. The Group has 36,000 employees and works with almost 8,600 professionals to treat more than nine million patients a year in its 350 facilities and five countries: France, Sweden, Norway, Denmark and Italy.
Ramsay Santé provides almost all medical and surgical specialties in 3 fields: Medicine, Surgery, Obstetrics (MSO), Follow-up Care and Rehabilitation (FCR) and Mental Health. In all its territories, the Group contributes to fitness and local care utilities. , as in Sweden, where the organization has more than a hundred local fitness centers. Safe and quality care is the Group’s priority in all the countries in which it operates. This is what has made it a benchmark in complex medicine, especially in outpatient surgery and Enhanced Recovery After Surgery (ERAS). The Group also invests more than €200 million a year in its facilities, whether in new surgical and imaging technologies or in the structure and modernisation of the facilities. To serve the most productive interests of patients, it is constantly innovating with new virtual teams and evolving its organizations towards the power of care.
Facebook: https://www. facebook. com/RamsaySanteInstagram: https://www. instagram. com/ramsaysanteTwitter: https://twitter. com/RamsaySanteLinkedIn: https://www. linkedin. com/company/ramsaysanteYouTube: https://www. youtube. com/c/RamsaySante
ISIN and Euronext Paris code: FR0000044471 Website: www. ramsaygds. fr
CONFERENCE CALL IN ENGLISH TODAY
At 19:30 (Paris time) – Dial the following numbers
From France: 33 (0)1 70 03 37
From Great Britain: (0)330 165 3641
From Australia: (0)2 7250 5433
From Sweden: (0)8 5664 2754
Access code: 510322 #
Investor Relations/Press Relations Analysts
Jérôme Brice Brigitte CachonTél. 33 1 87 86 21 88 Tel. 33 1 87 86 22 11Jerome. brice@ramsaysante. fr brigitte. cachon@ramsaysante. fr
Glossary
Constant reach
The consolidation perimeter update for incoming entities is as follows:
For the entries in the consolidation perimeter of the year, subtract the contribution of the acquisition of the aggregates of the year;
For last year’s acquisitions, deduct from the year the contribution of the acquisition of aggregates from the months preceding the month of the acquisition.
The update of the consolidation perimeter of the outgoing entities of the group is as follows:
For the deconsolidations of the year, the contribution of the deconsolidated entity is deducted from last year of the month of deconsolidation.
In the case of deconsolidation in the last year, the contribution of the deconsolidated entity will be deducted for the total of the last year. Replenishment at consistent exposure rates reflects a replenishment after conversion of the figure to the currencies of existing ones in the comparative matrix rates
The update in the consistent scope reflects an update in the figures that exclude the effect of adjustments to the accounting criteria during the period.
Recurring results of operations are the source of operating income rather than other sources of income and non-recurring expenses consisting of restructuring prices (charges and provisions), gains or losses on disposals or significant impairments of non-current, tangible or intangible assets; and another operational source of revenue and expenditure, such as a provision relating to a dispute in the main proceedings.
EBITDA corresponds to the source of operating income existing before depreciation and amortization (expenses and provisions in the source of income are grouped according to their nature).
Net monetary debt is gross monetary debt minus monetary assets.
Gross monetary debts are composed of:
borrowings from credit institutions, accrued interest;
leasing loans, accrued interest;
lease liabilities arising from IFRS 16;
fair hedging tools recorded on the balance sheet, net of taxes;
current monetary liabilities related to monetary current accounts with minority investors;
bank overdraft.
Financial consists of:
the fair of fair coverage tools recognized in the balance sheet, net of taxes;
current monetary rights related to monetary current accounts of minority investors;
Cash and cash equivalents, plus own shares held through the Group (considered as investment securities);
financial assets directly similar to loans and recognized as gross financial debt.
Annual monetary effects as of June 30, 2022
CONSOLIDATED DECLARATION OF COMPREHENSIVE INCOME
(million euros)
From July 1, 2021 to June 30, 2022
From July 1, 2020 to June 30, 2021
ROTATION
4 301,0
4 022,6
Staff pricing and profit sharing
(2 244,1)
(2 115,7)
Consumables purchased
(890. 7)
(818. 6)
Another operational source of income and expenses
(293. 6)
(226. 8)
Taxation
(129. 6)
(131. 8)
Renting
(84. 6)
(85,9)
EBITDA
658. 4
643. 8
Depreciation and amortization
(377. 3)
(371,8)
Profit from operations
281. 1
272,0
Restructuring costs
3. 5
(10. 6)
Result of the control of immovable and monetary property
6. 7
(10. 8)
Other sources of non-current income and expenditure
10. 2
(21. 4)
Operating income
291. 3
250. 6
Cost of gross monetary debt
(51. 8)
(52,9)
Source of cash income and money equivalents
0,6
0,8
Financial liabilities for leasing (IFRS16)
(72. 3)
(71. 1)
Cost of monetary debt
(123,5)
(123. 2)
Other monetary products
23. 1
0,6
Other monetary charges
(5. 7)
(24. 7)
Another monetary source of income and expenditure
17. 4
(24. 1)
Corporate tax
(57. 3)
(29. 5)
hare of the result of related companies
(0. 1)
—
CONSOLIDATED NET INCOME
127,8
73,8
Income and expenses recognized as equity
– Actuarial relating to post-employment benefits
(25. 7)
(25. 1)
– Change in the fair of hedging instruments
53,9
10. 3
– Foreign translation differences
7. 8
4. 1
– Other
—
—
– Effects of the tax on integral profit
(14. 3)
3. 5
Recognized results in heritage
21. 7
(7. 2)
TOTAL OVERALL RESULT
149,5
66,6
RESULT ATTRIBUTABLE TO (in euros)
From July 1, 2021 to June 30, 2022
From July 1, 2020 to June 30, 2021
– Net source of revenue Group share
118. 4
65,0
– Non-majority interests
9. 4
8. 8
NET LNGRESOS
127,8
73,8
NET PROFIT PER SHARE (in euros)
1. 07
0,59
DILUTED NET PROFIT PER SHARE (in euros)
1. 07
0,59
TOTAL OVERALL RESULT ATTRIBUTED TO (In euros)
From July 1, 2021 to June 30, 2022
From July 1, 2020 to June 30, 2021
– Overall result, Group participation
140. 1
57,8
– Non-majority interests
9. 4
8. 8
TOTAL OVERALL RESULT
149,5
66,6
CONSOLIDATED BALANCE SHEET – ASSETS
(million euros)
30-06-2022
30-06-2021
Willingness
2 065. 1
1 762. 6
Other intangible assets
244. 7
241. 2
Tangible capital goods
950. 2
918. 0
Right of use (IFRS16)
2 058. 2
2 079,8
Investments in companies
0,2
0,3
Other non-current monetary assets
119. 4
85,6
Deferred tax assets
94,7
125. 4
NON-CURRENT ASSET
5 532,5
5 212,9
Inventories
111. 2
111. 4
Customers and operating debtors
422. 0
323. 4
Other assets
574,0
406. 4
Current tax assets
4. 7
7. 6
Current monetary assets
11. 0
11. 6
Cash and money equivalents
132,5
608. 4
CURRENT ASSETS
1 255,4
1 468,8
TOTAL ASSETS
6 787,9
6 681,7
CONSOLIDATED BALANCE SHEET – LIABILITIES AND EQUITY
(million euros)
30-06-2022
30-06-2021
Share capital
82,7
82,7
issue premium
611. 2
611. 2
Consolidated reserves
400. 1
311. 4
Net source of revenue Group share
118. 4
65,0
Equity, sharing
1 212,4
1 070. 3
Non-majority interests
26. 3
28. 4
EQUITY
1 238,7
1 098,7
Loans and monetary debts
1 763,6
1 673,6
Debt for commitment to support minority interests
48,9
—
Non-current debt (IFRS16)
1 922. 3
1 940. 2
Provisions for post-employment benefits
115,7
157,6
Non-current provisions
164. 7
176,9
Other non-current liabilities
8. 9
32,6
Deferred tax liabilities
39,7
51. 2
NON-CURRENT LIABILITIES
4 063,8
4 032. 1
Provisions in force
48. 4
51,7
Suppliers and accounts payable
410. 8
343,8
Other liabilities
775. 6
901. 8
tax due
19. 2
16. 6
Current monetary debts
35. 4
38. 1
Outstanding debt (IFRS16)
196,0
198,9
CURRENT LIABILITIES
1485. 4
1,550. 9
TOTAL EQUITY AND LIABILITIES
6 787,9
6 681,7
STATEMENT OF CHANGES IN CONSOLIDATED EQUITY
(million euros)
SHARE CAPITAL
SHARE PREMIUM
RESERVES
RESULTS RECORDED DIRECTLY IN EQUITY
TOTAL COMPREHENSIVE RESULT OF THE YEAR
EQUITY, GROUP PARTICIPATION
NON-CONTROLLING PARTICIPATION
EQUITY
Heritage as of June 30, 2020
82,7
611. 2
369. 4
(64. 2)
13. 4
1 012,5
24,7
1 037,2
Capital accumulation (after deducting net emission prices from taxes)
—
—
—
—
—
—
—
—
Own actions
—
—
—
—
—
—
—
—
Loose and loose actions
—
—
—
—
—
—
—
—
Previous year to be assigned
—
—
13. 4
—
(13. 4)
—
—
—
Dividend distribution
—
—
—
—
—
—
(5. 0)
(5. 0)
Change in the consolidation perimeter
—
—
—
—
—
(0. 1)
(0. 1)
Total integral of the year
—
—
—
(7. 2)
65,0
57,8
8. 8
66,6
Heritage as of June 30, 2021
82,7
611. 2
382. 8
(71. 4)
65,0
1 070. 3
28. 4
1 098,7
Capital accumulation (after deducting net emission prices from taxes)
—
—
—
—
—
—
—
—
Own actions
—
—
—
—
—
—
—
—
Loose and loose actions
—
—
—
—
—
—
—
—
Previous year to be assigned
—
—
sixty-five
—
(65,0)
—
—
—
Dividend distribution
—
—
—
—
—
—
(12. 2)
(12. 2)
Change in the consolidation perimeter
—
—
—
2. 0
—
2. 0
0,7
2. 7
Total integral of the year
—
—
—
21. 7
118. 4
140. 1
9. 4
149,5
Heritage as of June 30, 2022
82,7
611. 2
447. 8
(47,7)
118. 4
1 212,4
26. 3
1 238,7
STATEMENT OF INCOME AND EXPENSES RECOGNIZED DIRECTLY IN THE NET WORTH
(million euros)
30-06-2020
Income and expenditure from 1 July 2020 to 30 June 2021
30-06-2021
Income and from July 1, 2021 to June 30, 2022
30-06-2022
Currency conversion differences
10. 6
4. 1
14. 7
(25. 8)
(11. 1)
Actuarial on post-employment benefits
(52,9)
(19. 0)
(71,9)
41,7
(30. 2)
Hedging Instruments Fair
(22. 5)
7. 7
(14. 8)
5. 8
(9. 0)
Another one
0,6
—
0,6
—
0,6
Income and expenses recognized as equity
(64. 2)
(7. 2)
(71. 4)
21. 7
(49. 7)
CONSOLIDATED CASH FLOW STATEMENT
(million euros)
From July 1, 2021 to June 30, 2022
From July 1, 2020 to June 30, 2021
Consolidated revenue of the organization
127,8
73,8
Depreciation and amortization
377. 3
371,8
Other sources of income and non-current expenses
(10. 2)
21. 4
Profit sharing of related companies
0,1
—
Another monetary source of income and expenditure
(17. 4)
24. 1
Rental Debt Financier (IFRS16)
72. 3
71. 1
Cost of monetary debt net monetary interest similar to rental debt
51. 2
52. 1
Income tax
57. 3
29,5
EBITDA
658. 4
643. 8
Non-monetary pieces similar to the popularity and recovery of provisions (non-monetary transactions)
3. 4
7. 9
Other sources of income and non-current expenditure paid
(10. 6)
(36. 4)
Change in non-current assets and liabilities
(9. 1)
9. 3
Cash before charge of net monetary debt and taxes
642. 1
624. 6
Income tax paid
(41. 7)
(21. 2)
Evolution of the current capital requirement
(337,9)
48,9
NET CASH FLOW FROM OPERATING ACTIVITIES: (A)
262,5
652. 3
Investment in tangible and intangible assets
(193. 6)
(176. 4)
Disposal of tangible and intangible assets
18. 2
2. 5
Acquisition of entities
(297. 4)
(73,6)
Divestment of entities
1. 0
65,5
Dividends obtained from unconsolidated companies
0,7
0,6
NET CASH USED IN INVESTMENT ACTIVITIES: (B)
(471. 1)
(181. 4)
Capital accumulation and factor premium: (a)
—
—
Dividends paid to minority shareholders of consolidated companies: (b)
(12. 2)
(5. 0)
Interest paid: (c)
(51. 8)
(52,9)
Financial income received: (d)
(1. 8)
0,8
Financial on rental debt (IFRS16): (e)
(72. 3)
(71. 1)
Debt issuance fees: (f)
(1. 1)
(9. 2)
Cash before replacing in loans: (g) = (A B a b c d e f)
(347,8)
333,5
Increase in indebtedness: (h)
100,0
1 560,3
Loan repayment: (i)
(12. 4)
(1 622,5)
Debt reduction (IFRS16): (j)
(212. 6)
(191. 0)
NET CASH USED IN FINANCING ACTIVITIES: (C) = a b c d e f h i j
(264. 2)
(390. 6)
(DECREASE)/NET INCREASE IN CASH AND CASH EQUIVALENTS: (A B C)
(472. 8)
80. 3
Exchange differences in money and equivalents of money maintained
(3. 1)
(10. 2)
Cash and cash equivalents at the beginning of the year
608. 4
538. 3
Cash and cash equivalents at year-end
132,5
608. 4
Net debt at the beginning of the year
3 230,5
3 372,5
Cash before loans: (g)
347,8
(333. 5)
Lease capitalization
—
—
Capitalization of borrowing costs
0,8
7. 0
Assets held for sale
—
—
Fair of hedging monetary instruments
(22. 4)
(2. 4)
Changes in scope and others
(28. 8)
(8. 5)
Rental liabilities (IFRS16)
182,0
195. 4
Net debt at the end of the year
3 709,9
3 230,5
Attachment
RAMSAY SANTE – Provisional annual effects at the end of June 2022